Videos,
Peter Kardel Shares Insight on ADVI’s Recent Study Analyzing Access to CAR-T Therapies
Recently, ADVI Health’s strategic analytics, value and economics (SAVEs) solution team conducted a study analyzing access to CAR-T therapies based on 2022 Medicare Advantage claims data and CAR-T claims data supported by Medicare Fee-For-Service (FFS) claims data from 2022-2024.
Hear more on the findings from Peter Kardel, vice president, SAVEs:
ADVI Health’s Peter Kardel breaks down the SAVEs team’s recent study on access to CAR-T therapies.
Panelists
Vice President, Strategic Analytics, Value and Economics (SAVEs)
Peter serves as the vice president of ADVI’s strategic analytics, value and economics, (SAVEs) team, where he analyzes real-time healthcare claims datasets, spanning multiple payers, (Medicare Parts A, B, and D; Medicare Advantage, and Medicaid), which includes 100% of all claims available.
Full Transcript
Peter Kardel: CAR-T cell therapy has been around for many years, and ADVI has been taking part in several investigations with stakeholders and those interested in learning more about CAR-T. Most recently, we had an interest in having a better understanding of potential socioeconomic factors that would be influencing the availability to CAR-T individuals.
We set out on an investigation to look at the racial disparities and other demographic factors that are influencing the receiving of this therapy. To do this, we looked at CAR-T claims from the 2022 Medicare Advantage, and we also looked at CAR-T claims from the Medicare Fee-For-Service (FFS) for 2022 to 2024. We eliminated clinical trials in order to look only at the commercial population, then we examined the demographic makeup of the Medicare Advantage and Fee-For-Service population.
We found that the Medicare Advantage population was slightly older, as well as more likely to be dual eligible and enrolled in Medicare for disability purposes. After controlling for these variables with some physical techniques, we looked at the racial makeup of the individuals. We found that white individuals were more likely to receive CAR-T than their non-white counterparts, specifically black individuals. We also looked at the distance that individuals were traveling to receive their CAR-T therapy, and the most interesting thing to note was that the black individuals were traveling significantly shorter distances to obtain their therapy compared to white individuals. So despite white individuals traveling a longer distance, they were still receiving it more often. There are a lot of factors that play into that, being that minorities are more likely to live in a high density population and the high density populations is where individuals are where the CAR-T centers are currently located.
We found that this research is interesting for stakeholders to understand. The discrepancies that we are seeing in those receiving CAR-T can be used to help push for equitable receiving of these very important therapies.